A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- PMID: 27067877
- PMCID: PMC11028850
- DOI: 10.1007/s00262-016-1835-4
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
Conflict of interest statement
The authors declare that they have no conflict of interest.
Comment in
-
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".Cancer Immunol Immunother. 2016 Jun;65(6):769-70. doi: 10.1007/s00262-016-1845-2. Epub 2016 May 19. Cancer Immunol Immunother. 2016. PMID: 27194054 Free PMC article. No abstract available.
References
-
- Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)
-
- Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)
-
- Pembrolizumab (keytruda) [package insert]. Whitehouse Station, NJ: Merk & Co., Inc. (2015)
-
- Keytruda (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ (2014)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
